100 related articles for article (PubMed ID: 35489377)
1. Pharmacokinetics, safety, tolerability, and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV-1 (IMPAACT P1093): results of an open-label, phase 1-2 trial.
Ruel TD; Acosta EP; Liu JP; Gray KP; George K; Montañez N; Popson S; Buchanan AM; Bartlett M; Dayton D; Anthony P; Brothers C; Vavro C; Singh R; Koech L; Vhembo T; Mmbaga BT; Pinto JA; Dobbels EFM; Archary M; Chokephaibulkit K; Ounchanum P; Deville JG; Hazra R; Townley E; Wiznia A;
Lancet HIV; 2022 May; 9(5):e332-e340. PubMed ID: 35489377
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics, safety, and tolerability of dispersible and immediate-release abacavir, dolutegravir, and lamivudine tablets in children with HIV (IMPAACT 2019): week 24 results of an open-label, multicentre, phase 1-2 dose-confirmation study.
Brooks KM; Kiser JJ; Ziemba L; Ward S; Rani Y; Cressey TR; Masheto GR; Cassim H; Deville JG; Ponatshego PL; Patel F; Aurpibul L; Barnabas SL; Mustich I; Coletti A; Heckman B; Krotje C; Lojacono M; Yin DE; Townley E; Moye J; Majji S; Acosta EP; Ryan K; Chandasana H; Brothers CH; Buchanan AM; Rabie H; Flynn PM;
Lancet HIV; 2023 Aug; 10(8):e506-e517. PubMed ID: 37541705
[TBL] [Abstract][Full Text] [Related]
3. Paediatric abacavir-lamivudine fixed-dose dispersible tablets and ritonavir-boosted lopinavir granules in neonates exposed to HIV (PETITE study): an open-label, two-stage, single-arm, phase 1/2, pharmacokinetic and safety trial.
Bekker A; Salvadori N; Rabie H; du Toit S; Than-In-At K; Groenewald M; Cressey R; Nielsen J; Capparelli EV; Lallemant M; Cotton MF; Cressey TR;
Lancet HIV; 2024 Feb; 11(2):e86-e95. PubMed ID: 38296364
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy at 240 weeks of different raltegravir formulations in children with HIV-1: a phase 1/2 open label, non-randomised, multicentre trial.
Nachman S; Alvero C; Teppler H; Homony B; Rodgers AJ; Graham BL; Fenton T; Frenkel LM; Browning RS; Hazra R; Wiznia AA;
Lancet HIV; 2018 Dec; 5(12):e715-e722. PubMed ID: 30527329
[TBL] [Abstract][Full Text] [Related]
5. Population Pharmacokinetic Modeling of Dolutegravir to Optimize Pediatric Dosing in HIV-1-Infected Infants, Children, and Adolescents.
Chandasana H; Thapar M; Hayes S; Baker M; Gibb DM; Turkova A; Ford D; Ruel T; Wiznia A; Fairlie L; Bwakura-Dangarembizi M; Mujuru H; Alvero C; Farhad M; Hazra R; Townley E; Buchanan A; Bollen P; Waalewijn H; Colbers A; Burger D; Acosta EP; Singh R;
Clin Pharmacokinet; 2023 Oct; 62(10):1445-1459. PubMed ID: 37603217
[TBL] [Abstract][Full Text] [Related]
6. Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV.
Mulligan N; Best BM; Wang J; Capparelli EV; Stek A; Barr E; Buschur SL; Acosta EP; Smith E; Chakhtoura N; Burchett S; Mirochnick M;
AIDS; 2018 Mar; 32(6):729-737. PubMed ID: 29369162
[TBL] [Abstract][Full Text] [Related]
7. Safety and pharmacokinetics of oral and long-acting injectable cabotegravir or long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study.
Gaur AH; Capparelli EV; Calabrese K; Baltrusaitis K; Marzinke MA; McCoig C; Van Solingen-Ristea RM; Mathiba SR; Adeyeye A; Moye JH; Heckman B; Lowenthal ED; Ward S; Milligan R; Samson P; Best BM; Harrington CM; Ford SL; Huang J; Crauwels H; Vandermeulen K; Agwu AL; Smith-Anderson C; Camacho-Gonzalez A; Ounchanum P; Kneebone JL; Townley E; Bolton Moore C; ;
Lancet HIV; 2024 Apr; 11(4):e211-e221. PubMed ID: 38538160
[TBL] [Abstract][Full Text] [Related]
8. Acceptability and tolerability of long-acting injectable cabotegravir or rilpivirine in the first cohort of virologically suppressed adolescents living with HIV (IMPAACT 2017/MOCHA): a secondary analysis of a phase 1/2, multicentre, open-label, non-comparative dose-finding study.
Lowenthal ED; Chapman J; Ohrenschall R; Calabrese K; Baltrusaitis K; Heckman B; Yin DE; Agwu AL; Harrington C; Van Solingen-Ristea RM; McCoig CC; Adeyeye A; Kneebone J; Chounta V; Smith-Anderson C; Camacho-Gonzalez A; D'Angelo J; Bearden A; Crauwels H; Huang J; Buisson S; Milligan R; Ward S; Bolton-Moore C; Gaur AH; ;
Lancet HIV; 2024 Apr; 11(4):e222-e232. PubMed ID: 38538161
[TBL] [Abstract][Full Text] [Related]
9. HIV-1 reservoir size after neonatal antiretroviral therapy and the potential to evaluate antiretroviral-therapy-free remission (IMPAACT P1115): a phase 1/2 proof-of-concept study.
Persaud D; Bryson Y; Nelson BS; Tierney C; Cotton MF; Coletti A; Jao J; Spector SA; Mirochnick M; Capparelli EV; Costello D; Szewczyk J; Nicodimus N; Stranix-Chibanda L; Kekitiinwa AR; Korutaro V; Reding C; Carrington MN; Majji S; Yin DE; Jean-Philippe P; Chadwick EG
Lancet HIV; 2024 Jan; 11(1):e20-e30. PubMed ID: 38061376
[TBL] [Abstract][Full Text] [Related]
10. HIV viral suppression in children and adolescents 2 years after transition to dolutegravir: a multicentre cohort study.
Devendra A; Kohler M; Letsika M; Khooa H; Motaboli L; Lerotholi M; Tschumi N; Labhardt ND; Brown JA
AIDS; 2024 Jun; 38(7):1013-1023. PubMed ID: 38381717
[TBL] [Abstract][Full Text] [Related]
11. Efficacy, safety, and tolerability of dolutegravir-based ART regimen in Durban, South Africa: a cohort study.
Hurbans N; Naidoo P
BMC Infect Dis; 2024 Mar; 24(1):343. PubMed ID: 38515041
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic Data of Dolutegravir in Second-line Treatment of Children With Human Immunodeficiency Virus: Results From the CHAPAS4 Trial.
Bevers LAH; Waalewijn H; Szubert AJ; Chabala C; Bwakura-Dangarembizi M; Makumbi S; Nangiya J; Mumbiro V; Mulenga V; Musiime V; Burger DM; Gibb DM; Colbers A
Clin Infect Dis; 2023 Nov; 77(9):1312-1317. PubMed ID: 37280040
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics, Tolerability, and Safety of Doravirine and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Fixed-Dose Combination Tablets in Adolescents Living With HIV: Week 24 Results From IMPAACT 2014.
Melvin AJ; Yee KL; Gray KP; Yedla M; Wan H; Tobin NH; Teppler H; Campbell H; McCarthy K; Scheckter R; Aurpibul L; Ounchanum P; Rungmaitree S; Cassim H; McFarland E; Flynn P; Cooper E; Krotje C; Townley E; Moye J; Best BM;
J Acquir Immune Defic Syndr; 2023 Feb; 92(2):153-161. PubMed ID: 36215957
[TBL] [Abstract][Full Text] [Related]
14. Twice-Daily Dosing of Dolutegravir in Infants on Rifampicin Treatment: A Pharmacokinetic Substudy of the EMPIRICAL Trial.
Jacobs TG; Mumbiro V; Cassia U; Zimba K; Nalwanga D; Ballesteros A; Domínguez-Rodríguez S; Tagarro A; Madrid L; Mutata C; Chitsamatanga M; Bwakura-Dangarembizi M; Passanduca A; Buck WC; Nduna B; Chabala C; Najjingo E; Musiime V; Moraleda C; Colbers A; Mujuru HA; Rojo P; Burger DM;
Clin Infect Dis; 2024 Mar; 78(3):702-710. PubMed ID: 37882611
[TBL] [Abstract][Full Text] [Related]
15. Early Effects of Scaling Up Dolutegravir-Based ARV Regimens Among Children Living with HIV in Malawi.
Makonokaya L; Maida A; Kalitera LU; Wang A; Kapanda L; Kayira D; Bottoman M; Nkhoma H; Dunga S; Joaki Z; Chamanga R; Nkanaunena K; Hrapcak S; Nyirenda R; Chiwandira B; Maulidi M; Woelk G; Machekano R; Maphosa T
AIDS Behav; 2024 Jun; 28(6):2148-2155. PubMed ID: 38615099
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetic modeling of dolutegravir/lamivudine to support a once-daily fixed-dose combination regimen in virologically suppressed adults living with HIV-1.
Chandasana H; Singh R; Adkison K; Ait-Khaled M; Pene Dumitrescu T
Antimicrob Agents Chemother; 2024 May; 68(5):e0150423. PubMed ID: 38587380
[TBL] [Abstract][Full Text] [Related]
17. Effect of fosamprenavir-ritonavir on the pharmacokinetics of dolutegravir in healthy subjects.
Song I; Borland J; Chen S; Peppercorn A; Wajima T; Piscitelli SC
Antimicrob Agents Chemother; 2014 Nov; 58(11):6696-700. PubMed ID: 25155604
[TBL] [Abstract][Full Text] [Related]
18. Comorbidity and concomitant medication use in an integrase strand transfer inhibitor naïve cohort on first-line dolutegravir-based antiretroviral therapy.
Hurbans N; Naidoo P
Pan Afr Med J; 2024; 47():137. PubMed ID: 38881766
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of Generic Pediatric Dolutegravir Dispersible Tablet in Thai Young Children Living With HIV Weighing Below Twenty Kilograms.
Rungsapphaiboon A; Wacharachaisurapol N; Anugulruengkitt S; Sirikutt P; Phasomsap C; Tawan M; Saisaengjan C; Na Nakorn Y; Paiboon N; Songtaweesin WN; Tawon Y; Cressey TR; Puthanakit T;
Pediatr Infect Dis J; 2024 May; ():. PubMed ID: 38768047
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of Single-Dose Versus Double-Dose Dolutegravir After Switching From a Failing Efavirenz-Based Regimen.
Griesel R; Banda CG; Zhao Y; Omar Z; Wiesner L; Meintjes G; Sinxadi P; Maartens G
J Acquir Immune Defic Syndr; 2024 May; 96(1):85-91. PubMed ID: 38372621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
